PARP1 and hyperinsulinemic hypoglycemia, familial, 4: Evidence has indicated the synthetic lethality of using the DNA-PCK inhibitor [33], Pol β inhibitor [34], and PARP inhibitor [35] from cell line or preclinical studies in tumors with MMR deficiency and somatic mutations.